Stiefel Laboratories will acquire Barrier Therapeutics for approximately $148 million. The parties expect the transaction to close by the end of the third quarter of 2008. “This acquisition demonstrates our continued commitment to advancing the field of therapeutic dermatology,” said Charles W. Stiefel, chairman and chief executive officer of Stiefel Laboratories. “We are very impressed with Barrier Therapeutics’ innovative products and pipeline. This strategic move wi...